A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumours

Conditions: Advanced Solid Tumours That Are MTAP Deficient Interventions: Drug: AZD3470 Sponsors: AstraZeneca Not yet recruiting

Source: ClinicalTrials.gov - November 14, 2023 Category: Research Source Type: clinical trials